<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Targeting Resistance to Advance Preclinical Oncology Drug Discovery

Expert Solutions for Tackling Drug Resistance Challenges

Drug resistance is a major challenge in treating advanced and hematological cancers. Crown Bioscience's extensive collection of resistant models—both de novo and acquired—empowers clients to deeply understand resistance mechanisms, particularly in pretreated and liquid tumors.

By integrating CRISPR engineering and drug-mediated induced resistance with comprehensive biomarker analysis, including multi-omics and spatial biology, we provide precise characterization of resistance phenotypes. Our service also offers high-throughput screening and advanced imaging capabilities, enabling the development of therapies designed to overcome resistance and significantly improve clinical outcomes.

Transforming Cancer Drug Resistance

Overcome drug resistance in your preclinical research with our diverse models, including patient-derived xenografts (PDX). Use our oncology databases to find the most relevant models and access extensive profiling and pharmacologic data. Enhance your research with advanced biomarker analysis, multi-omics, spatial biology assays, and data science platforms, driving effective drug discovery.

webinar-4-steps

Webinar

Four-Step Preclinical Strategy to Tackle Cancer Drug Resistance

Explore multiple solutions for optimal drug resistance model development

Our unique four-step approach offers personalized strategies to address various drug resistance challenges, facilitating the successful acceleration of your project. By analyzing intrinsic and acquired resistance across diverse therapeutic types and molecular targets, we craft tailored solutions that enhance treatment efficacy.



Integrated Services Approach to Developing New and Clinically Relevant Models

Navigate the complexities of drug resistance using our strategic solutions and robust resources, designed to accelerate your drug development journey, ensuring you achieve success with greater efficiency.

Our customized integrated solutions provide you with a comprehensive suite of resistance models across in vitro, in vivo, ex vivo, and in silico platforms, supported by a living biobank of over 30 cancer types. Our ongoing R&D efforts continually expand our catalog, and we offer custom model development to meet specific research needs. By integrating biomarker strategies, we help predict clinical responses, enabling the identification of translatable solutions and accelerating research progress.

Our Customers Love Us

We are proud to boast the best Customer Experience in the Industry, explore our data below.

Studies <br>Completed

Studies
Completed

This data point indicates the total number of studies in Q2 2023 that the CSAT, Customer Effort, and Customer Expectation scores are measured against.

Studies
Completed

888

Customer <br>Satisfaction

Customer
Satisfaction

Also known as CSAT, this metric indicates how satisfied customers are with the complete Crown Bioscience customer experience.

Customer
Satisfaction

96%

Customer <br>Effort

Customer
Effort

The Customer Effort Score (CES) is a metric that measures how easy it was to work with Crown Bioscience.

Customer
Effort

96%

Explore our monthly Customer Satisfaction Report

Discuss Your Drug Resistance Project

Related Resources

thumb-clinically-aligned

Flyer

Clinically Aligned Pretreated PDX Models

kras-inhibitor

Application Note

Breaking the Barrier of KRASG12C Inhibitor Resistance

cell-derived-xenograft-models

Application Note

HCC827 NSCLC Cell Line Derived Xenograft Model

drug-resistance

Blog

Combating Cancer Drug Resistance with In Vivo Models